| | | |   | | | | By Damian Garde Adobe The latest Alzheimer’s disease treatment from Eisai and Biogen needs to be cheaper than $20,000 a year to be cost-effective, ICER says. Read More | | By Ambar Castillo Jae C. Hong/AP Deaths from Covid-19 and drug overdoses drove U.S. life expectancy to fall to 76.4 years in 2021, the lowest level since 1996. Read More | | By Damian Garde and Adam Feuerstein We look back on the biggest biotech stories of the past year and how the industry seems stuck in a sentiment rut. Read More | | Sponsored Insight by Tegus Perspectives on the monoclonal antibody treatment for Alzheimer’s disease, lecanemab Drugmakers Biogen Inc. (BIIB) and Eisai Co., Ltd. (ESALY) announced that a monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the development of cognitive decline. Tegus was the most efficient way for investors and corporations alike to quickly understand Biogen and Eisai's perspectives, their pipeline, and where the antibody treatment fits in the treatment landscape. Tegus hosts thousands of 1:1 conversations with top physicians, industry executives, and custom-sourced KOLs, so primary research is just a click away. Learn more with a free Tegus trial. | | By Andrew Joseph Caitlin O'Hara for STAT Under new rules, clinics giving methadone for opioid addiction don't have to require daily visits. But some resist the flexibility. Read More | |
No comments